EUVIMEDDécouvrir EUVIMED
Crossref

SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathway

Gonghua Qi, Hanlin Ma, Kai Teng, Panpan Gai, Yanmin Gong, Jingying Chen, Xia Luo, Beihua Kong

Apoptosis · 2025

DOI: 10.1007/s10495-024-02027-3 ↗

At a glance

Journal article in Apoptosis, 2025. Written by Gonghua Qi and 7 co-authors. Institution: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, China. Major MEDLINE topics: Cisplatin, Drug Resistance, Neoplasm, Ovarian Neoplasms, TOR Serine-Threonine Kinases. Cited 14 times so far (Crossref); 27 references. Funded by: National Natural Science Foundation of China, Nature Science Foundation of Shandong Province, the Tai-Shan Scholar Program from Shandong Province.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Ovarian cancer caused the highest cancer-related mortality among female reproductive system malignancies. Platinum-based chemotherapy is still the footstone of the chemotherapy for ovarian cancer. However, the molecular mechanisms underlying cisplatin insensitivity and resistance remain unclear. SHC SH2 domain-binding protein 1 (SHCBP1) plays critical roles in the progression and drug resistance of different types of cancer. However, the biological function of SHCBP1 in ovarian cancer progression and cisplatin resistance remains obscure. In this study, we found that SHCBP1 was upregulated in ovarian cancer and the upregulated SHCBP1 has growth-promoting effect on ovarian cancer cells. Furthermore, SHCBP1 silencing sensitize ovarian cancer cells to cisplatin (hereafter referred to as CDDP). Mechanism analysis revealed that SHCBP1 activated the Akt/mTOR pathway and further inhibited autophagy in ovarian cancer cells. Meanwhile, autophagy inhibitors combined with SHCBP1 knockdown enhances CDDP sensitivity. In addition, knockdown of SHCBP1 restricted the proliferation of tumors and increased the cisplatin sensitivity in vivo. These findings suggested that upregulated SHCBP1 promoted the proliferation and CDDP resistance of ovarian cancer. The combination of SHCBP1 inhibition and cisplatin treatment might lead to substantial progress in ovarian cancer targeted therapy.

Subjects

MeSH terms (MEDLINE)

CisplatinDrug Resistance, NeoplasmOvarian NeoplasmsTOR Serine-Threonine KinasesAutophagyProto-Oncogene Proteins c-aktShc Signaling Adaptor ProteinsFemaleHumansCell Line, TumorAnimalsSignal TransductionCell ProliferationAntineoplastic AgentsMiceMice, NudeGene Expression Regulation, Neoplastic

Author keywords

AKT/mTORAutophagyCisplatin sensitivityOvarian cancerSHCBP1

Substances

CisplatinTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktMTOR protein, humanSHCBP1 protein, humanAntineoplastic AgentsShc Signaling Adaptor Proteins

Authors and institutions

  • Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, China.
  • Gynecologic Oncology Key Laboratory of Shandong Province, Qilu Hospital, Shandong University, Jinan, 250012, China.
  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, 250117, China.
  • 71217 of the Chinese People's Liberation Army, Laiyang, 265200, China.
  • Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, China. luoxia@email.sdu.edu.cn.
  • Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, China. kongbeihua@sdu.edu.cn.

Funding

  • National Natural Science Foundation of China
  • Nature Science Foundation of Shandong Province
  • the Tai-Shan Scholar Program from Shandong Province
  • the Tai‐Shan Scholar Program from Shandong Province

Cite

APA

Qi, G., Ma, H., Teng, K., Gai, P., Gong, Y., Chen, J., Luo, X., & Kong, B. (2025). SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathway. Apoptosis. https://doi.org/10.1007/s10495-024-02027-3

Vancouver

Qi G, Ma H, Teng K, Gai P, Gong Y, Chen J, et al. SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathway. Apoptosis. 2025. doi:10.1007/s10495-024-02027-3

BibTeX
@article{Qi2025,
  author = {Qi, Gonghua and Ma, Hanlin and Teng, Kai and Gai, Panpan and Gong, Yanmin and Chen, Jingying and Luo, Xia and Kong, Beihua},
  title = {SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathway},
  journal = {Apoptosis},
  year = {2025},
  doi = {10.1007/s10495-024-02027-3}
}
Start for free →